Investigating citrullinated proteins in tumour cell lines

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Jiang, Zhongmin ^a   Cui, Yazhou ^b   Wang, Lin ^b   Zhao, Yan ^b   Yan, Suhua ^a   Chang, Xiaotian ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Citrullination; Peptidylarginine deiminases; Tumour

Indexed keywords

ALPHA ENOLASE; ARGININE; BETA TUBULIN; CHAPERONIN 60; CITRULLINE; CYTOKERATIN 8; LYMPHOCYTE RECEPTOR; VIMENTIN;

ARTICLE; CANCER CELL CULTURE; CELL LYSATE; COCARCINOGENESIS; HELA CELL; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MASS SPECTROMETRY; PROTEIN ANALYSIS; TWO DIMENSIONAL ELECTROPHORESIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

BLOTTING, WESTERN; CITRULLINE; HUMANS; IMMUNOPRECIPITATION; NEOPLASMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EID: 84885001470     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-260     Document Type: Article

References (40)

1. György B, Tóth E, Tarcsa E, Falus A, Buzás EI. Citrullination: a posttranslational modification in health and disease. Int J Biochem Cell Biol 2006, 38:1662-1677. 10.1016/j.biocel.2006.03.008, 16730216.
2. Takahara H, Okamoto H, Sugawara K. Specific modification of the functional arginine residue in soybean trypsin inhibitor (Kunitz) by peptidylarginine deiminase. J Biol Chem 1985, 260:8378-8383.
3. Kubilus J, Waitkus RF, Baden HP. Partial purification and specificity of an arginine-converting enzyme from bovine epidermis. Biochim Biophys Acta 1980, 615:246-251. 10.1016/0005-2744(80)90027-3, 7426662.
4. Inagaki M, Takahara H, Nishi Y, Sugawara K, Sato C. Ca2+-dependent deimination-induced disassembly of intermediate filaments involves specific modification of the amino-terminal head domain. J Biol Chem 1989, 264:18119-18127.
5. Takahara H, Tsuchida M, Kusubata M, Akutsu K, Tagami S, Sugawara K. Peptidylarginine deiminase of the mouse. Distribution, properties, and immunocytochemical localization. J Biol Chem 1989, 264:13361-13368.
6. Arita K, Hashimoto H, Shimizu T, Nakashima K, Yamada M, Sato M. Structural basis for Ca(2+)-induced activation of human PAD4. Nat Struct Mol Biol 2004, 11:777-783. 10.1038/nsmb799, 15247907.
7. Chavanas S, Méchin MC, Nachat R, Adoue V, Coudane F, Serre G, Simon M. Peptidylarginine deiminases and deimination in biology and pathology: relevance to skin homeostasis. J Dermatol Sci 2006, 44:63-72. 10.1016/j.jdermsci.2006.07.004, 16973334.
8. Bicker KL, Thompson PR. The protein arginine deiminases: structure, function, inhibition, and disease. Biopolymers 2013, 99:155-163. 10.1002/bip.22127, 23175390.
9. Chang X, Han J. Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors. Mol Carcinog 2006, 45:183-196. 10.1002/mc.20169, 16355400.
10. Chang X, Han J, Pang L, Zhao Y, Yang Y, Shen Z. Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer 2009, 9:40. 10.1186/1471-2407-9-40, 2637889, 19183436.
11. Baka Z, Barta P, Losonczy G, Krenács T, Pápay J, Szarka E, Sármay G, Babos F, Magyar A, Géher P, Buzás EI, Nagy G. Specific expression of PAD4 and citrullinated proteins in lung cancer is not associated with anti-CCP antibody production. Int Immunol 2011, 23:405-414. 10.1093/intimm/dxr026, 21602177.
12. Chang X, Hou X, Pan J, Fang K, Wang L. Expression of peptidylarginine deiminase type 4 in Ec. Int J Biomed Sci 2011, 7:769-781.
13. Cherrington BD, Zhang X, McElwee JL, Morency E, Anguish LJ, Coonrod SA. Potential role for PAD2 in gene regulation in breast cancer cells. PLoS One 2012, 7:e41242. 10.1371/journal.pone.0041242, 3404060, 22911765.
14. Mohanan S, Cherrington BD, Horibata S, McElwee JL, Thompson PR, Coonrod SA. Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis. Biochem Res Int 2012, 2012:895343. 3457611, 23019525.
15. Li P, Yao H, Zhang Z, Li M, Luo Y, Thompson PR, Gilmour DS, Wang Y. Regulation of p53 target gene expression by peptidylarginine deiminase. Mol Cell Biol 2008, 28:4745-4758. 10.1128/MCB.01747-07, 2493360, 18505818.
16. Yao H, Li P, Venters BJ, Zheng S, Thompson PR, Pugh BF, Wang Y. Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. J Biol Chem 2008, 283:20060-20068. 10.1074/jbc.M802940200, 2459274, 18499678.
17. Li P, Wang D, Yao H, Doret P, Hao G, Shen Q, Qiu H, Zhang X, Wang Y, Chen G, Wang Y. Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression. Oncogene 2010, 29:3153-3162. 10.1038/onc.2010.51, 2913128, 20190809.
18. Tanikawa C, Espinosa M, Suzuki A, Masuda K, Yamamoto K, Tsuchiya E, Ueda K, Daigo Y, Nakamura Y, Matsuda K. Regulation of histone modification and chromatin structure by the p53-PADI4 pathway. Nat Commun 2012, 3:676.
19. Guo Q, Bedford MT, Fast W. Discovery of peptidylarginine deiminase-4 substrates by protein array: antagonistic citrullination and methylation of human ribosomal protein S2. Mol Biosyst 2011, 7:2286-2295. 10.1039/c1mb05089c, 3251905, 21584310.
20. Chang X, Fang K. PADI4 and tumorigenesis. Cancer Cell Int 2010, 10:7. 10.1186/1475-2867-10-7, 2845578, 20222985.
21. Chang X, Yamada R, Suzuki A, Kochi Y, Sawada T, Yamamoto K. Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology 2005, 44:1374-1382. 10.1093/rheumatology/kei023, 16105911.
22. Chang X, Jian X, Yan X. Expression and citrullination of keratin in synovial tissue of rheumatoid arthritis. Rheumatol Int 2009, 29:1337-1342. 10.1007/s00296-009-0863-1, 19194706.
23. Chang X, Yamada R, Sawada T, Suzuki A, Kochi Y, Yamamoto K. The inhibition of antithrombin by peptidylarginine deiminase 4 may contribute to pathogenesis of rheumatoid arthritis. Rheumatology 2005, 44:293-298. 10.1093/rheumatology/keh473, 15561738.
24. Ordóñez A, Yélamos J, Pedersen S, Miñano A, Conesa-Zamora P, Kristensen SR, Stender MT, Thorlacius-Ussing O, Martínez-Martínez I, Vicente V, Corral J. Increased levels of citrullinated antithrombin in plasma of patients with rheumatoid arthritis and colorectal adenocarcinoma determined by a newly developed ELISA using a specific monoclonal antibody. Thromb Haemost 2010, 104:1143-1149. 10.1160/TH10-05-0297, 20838745.
25. Yan X, Yin L, Wang Y, Zhao Y, Chang X. The low binding affinity of ADAMTS4 for citrullinated fibronectin may contribute to the destruction of joint cartilage in rheumatoid arthritis. Clin Exp Rheumatol 2013, 31:201-206.
26. Zhang Y, Li M, Liu Y, Han N, Zhang K, Xiao T, Cheng S, Gao Y. ENO1 protein levels in the tumor tissues and circulating plasma samples of non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 2010, 13:1089-1093.
27. He P, Naka T, Serada S, Fujimoto M, Tanaka T, Hashimoto S, Shima Y, Yamadori T, Suzuki H, Hirashima T, Matsui K, Shiono H, Okumura M, Nishida T, Tachibana I, Norioka N, Norioka S, Kawase I. Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer. Cancer Sci 2007, 98:1234-1240. 10.1111/j.1349-7006.2007.00509.x, 17506794.
28. Tsai ST, Chien IH, Shen WH, Kuo YZ, Jin YT, Wong TY, Hsiao JR, Wang HP, Shih NY, Wu LW. ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction. Eur J Cancer 2010, 46:1712-1723. 10.1016/j.ejca.2010.03.018, 20435467.
29. Avni R, Cohen B, Neeman M. Hypoxic stress and cancer: imaging the axis of evil in tumor metastasis. NMR Biomed 2011, 24:569-581. 3558740, 21793071.
30. Ghosh JC, Siegelin MD, Dohi T, Altieri DC. Heat shock protein 60 regulation of the mitochondrial permeability transition pore in tumor cells. Cancer Res 2010, 70:8988-8993. 10.1158/0008-5472.CAN-10-2225, 2982903, 20978188.
31. Ghosh JC, Dohi T, Kang BH, Altieri DC. Hsp60 regulation of tumor cell apoptosis. J Biol Chem 2008, 283:5188-5194.
32. Castilla C, Congregado B, Conde JM, Medina R, Torrubia FJ, Japón MA, Sáez C. Immunohistochemical expression of Hsp60 correlates with tumor progression and hormone resistance in prostate cancer. Urology 2010, 76:1017.
33. Desmetz C, Bibeau F, Boissière F, Bellet V, Rouanet P, Maudelonde T, Mangé A, Solassol J. Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ. J Proteome Res 2008, 7:3830-3837. 10.1021/pr800130d, 18683965.
34. Chun JN, Choi B, Lee KW, Lee DJ, Kang DH, Lee JY, Song IS, Kim HI, Lee SH, Kim HS, Lee NK, Lee SY, Lee KJ, Kim J, Kang SW. Cytosolic Hsp60 is involved in the NF-kappaB-dependent survival of cancer cells via IKK regulation. PLoS One 2010, 5:e9422. 10.1371/journal.pone.0009422, 2843631, 20351780.
35. Hall A. The cytoskeleton and cancer. Cancer Metastasis Rev 2009, 28:5-14. 10.1007/s10555-008-9166-3, 19153674.
36. Kelley MJ, Li S, Harpole DH. Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer. J Natl Cancer Inst 2001, 93:1886-1888. 10.1093/jnci/93.24.1886, 11752014.
37. Ohishi Y, Oda Y, Basaki Y, Kobayashi H, Wake N, Kuwano M, Tsuneyoshi M. Expression of beta-tubulin isotypes in human primary ovarian carcinoma. Gynecol Oncol 2007, 105:586-592. 10.1016/j.ygyno.2007.01.044, 17343904.
38. Hadfield JA, Ducki S, Hirst N, McGown AT. Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res 2003, 5:309-325.
39. Walker LC, Harris GC, Holloway AJ, McKenzie GW, Wells JE, Robinson BA, Morris CM. Cytokeratin KRT8/18 expression differentiates distinct subtypes of grade 3 invasive ductal carcinoma of the breast. Cancer Genet Cytogenet 2007, 178:94-103. 10.1016/j.cancergencyto.2007.06.002, 17954264.
40. Schutte B, Henfling M, Kölgen W, Bouman M, Meex S, Leers MP, Nap M, Björklund V, Björklund P, Björklund B, Lane EB, Omary MB, Jörnvall H, Ramaekers FC. Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 2004, 297:11-26. 10.1016/j.yexcr.2004.02.019, 15194421.